Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Batoclimab in Active Thyroid Eye Disease
jRCT2071240006Phase 3Active, not recruiting
- Sponsor
- Immunovant, Inc.
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, triple-blind trial in Graves Orbitopathy (GO) comparing Batoclimab with Placebo (2 arms). Primary endpoint: Proptosis responder rate at Week 24. Started Jul 2024; status: active, not recruiting.
02
Drugs
batoclimab
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on jRCT2071240006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240006.